Clincosm LogoSign in Get a demo

Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05783778
Collaborator
(none)
200
Enrollment
2
Arms
18
Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Acne vulgaris is one if the most common chronic inflammatory skin disorders.Acne is characterized by forming of inflammatory and non inflammatory lesions mainly on the Face,neck,arms, upper trunk and back

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Free testosterone levels and toxoplasma igG
 N/A

Detailed Description

One of the hidden hormonal imbalance is Toxoplasma infection.Toxoplasmosis is a zoonotic infection the definite host is feline whereas human and other warm blooded animals are intermediate host . Endocrine alterations occuring during toxoplasmosis can be a hidden cause of acne vulgaris

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of the Role of Latent Toxoplasmosis in Female Patients With Active Acne Vulgaris
Anticipated Study Start Date :
Jun 1, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Toxoplasmosis seropositive female patients with active acne vulgaris

Diagnostic Test: Free testosterone levels and toxoplasma igG
Free testosterone levels and toxoplasma igG in serum by ELISA
Experimental: Toxoplasmosis seronegative in female patients with active acne vulgaris

Diagnostic Test: Free testosterone levels and toxoplasma igG
Free testosterone levels and toxoplasma igG in serum by ELISA

Outcome Measures

Primary Outcome Measures

  1. Measuring Toxoplasma igG and free testosterone in acne vulgaris patients and controls [One month]

    Detect if the toxoplasma latent infection can be associated with disease severity and hormonal disturbances in acne vulgaris female patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Female patients with active acne vulgaris
Exclusion Criteria:
  • Patients with history of hormonal treatment Patients received anti toxoplasma therapy Patients with dermatological diseases caused by hormonal disturbances Pregnant and lactating patients

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Zineb Gamee Aly Ahmed, Zienab Gamea Ali Ahmed, Sohag University
ClinicalTrials.gov Identifier:
NCT05783778
Other Study ID Numbers:
  • Soh-Med-23-03-05MS
First Posted:
Mar 24, 2023
Last Update Posted:
Mar 24, 2023
Last Verified:
Mar 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Toxoplasmosis
Acne Vulgaris
Testosterone

Study Results

No Results Posted as of Mar 24, 2023